Prenatal administration of vitamin A alters pulmonary and plasma levels of vascular endothelial growth factor in the developing mouse by Pinto, Maria de Lurdes et al.
ORIG INAL ART ICLE
Prenatal administration of vitamin A alters pulmonary and
plasma levels of vascular endothelial growth factor in the
developing mouse
Maria de Lurdes Pinto*,, Paula Rodrigues*,, Ana Cla´udia Coelho*, Maria dos Anjos Pires*,
Dario Loureiro dos Santos, Carlos Gonc¸alves and Vasco Anto´nio Bairos
*Department of Veterinary Sciences and Centre for Studies on Agricultural and Veterinary Sciences, Department of Biology, University
of Tra´s-os-Montes e Alto Douro, Vila Real, Portugal and

Institute of Histology and Embryology and Centre for Histophysiology,
Experimental Pathology and Developmental Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Vitamin A and its related compounds, the retinoids, play a
unique role in mammalian embryonic and foetal develop-
ment and are essential for both cellular differentiation and
the establishment of normal morphogenesis (Rodrigues et al.
2004).
Vessel development in the early lung determines lung
structure maturation, and both undisturbed angiogenesis and
vasculogenesis are necessary for the successful building of
the organ (Healy et al. 2000; Voelkel et al. 2006). Several
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Summary
Vitamin A and the retinoids play a unique role in mammalian embryonic and foetal
development and are essential for both cellular differentiation and the establishment
of normal morphogenesis. Vascular endothelial growth factor (VEGF) is a known
potent mitogenic factor that plays a key role in lung development and function
maintenance. In order to contribute to a better knowledge of the modulating effects
of vitamin A in lung development, we investigated the effects of the antenatal admin-
istration of vitamin A on VEGF expression in lungs and plasma from foetuses and
neonates. Pregnant mice were subjected to subcutaneous administration of vitamin A
on the 12th gestational day. The lungs and plasma from foetuses and neonates were
collected daily from the 15th gestational day till the day of birth. Our results show
that vitamin A modulates VEGF concentrations both in lungs and plasma. Statisti-
cally significant differences were observed at gestational days 15 (P = 0.004 for
lungs; P < 0.0001 for plasma), 16 (P < 0.0001 for lungs and plasma) and 18
(P < 0.0001 for lungs; P < 0.05 for plasma). Vitamin A tends to increase the expres-
sion of this factor in the lung, particularly during the critical period of perinatal
adaptation to postnatal life. These effects seem to be spatial and temporally regu-
lated, and point out to the important role of vitamin A during lung development.
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growth factor (VEGF), glucocorticoid and retinoic acid (RA)
have been implicated in regulating lung maturation and vas-
cular development (Morrisey & Savani 2003).
It has been demonstrated that RA is required for the
normal alveolar development in the mouse, and exogenous
administration of RA restores alveolar architecture to the
lungs of dexamethasone-treated mice (Hind & Maden 2004;
Maden & Hind 2004; Maden 2006). Retinoic acid main-
tains alveolar development in mice treated with an angio-
genesis inhibitor (Cho et al. 2005), and is required to
control endothelial cell maturation and cell cycle progression
during vasculogenesis and angiogenesis (Lai et al. 2003).
Vascular endothelial growth factor is a potent mediator
of angiogenesis, which has multiple effects in lung develop-
ment and physiology. It has been reported that lung pre-
sents the highest level of VEGF gene expression among
normal tissues (Kaner et al. 2000; Voelkel et al. 2006).
Vascular endothelial growth factor is also involved in the
pathophysiology of some of the most common respiratory
disorders (Papaioannou et al. 2006). One of these condi-
tions is bronchopulmonary dysplasia (BPD). Infants dying
from BPD have reduced pulmonary levels of VEGF (Bhatt
et al. 2001), and intrauterine or postnatal intratracheal
instillation of VEGF protects preterm mice against respira-
tory distress syndrome (RDS) (Compernolle et al. 2002). It
was verified that VEGF plays a central role in the epi-
thelial–endothelial interactions that are critical for normal
lung development (Acarregui et al. 1999; Brown et al.
2001; Compernolle et al. 2002; Zhao et al. 2005). Vascular
endothelial growth factor seems to interfere in a different
manner, depending on its amount, the location and the
underlying physiological or pathological process in lung
tissue (Papaioannou et al. 2006). Recent studies have corre-
lated RA and VEGF during lung development, hypothesiz-
ing that inhibition of alveolar development is associated
with a block in angiogenesis due to the down-regulation of
VEGF and VEGFR2, which is prevented by treatment with
RA (Cho et al. 2005). It has been shown that RA regulates
the expression of several signalling molecules including
VEGF in tissues such as skin and brain development
(Maden et al. 1996; Lachgar et al. 1999; Diaz et al. 2000).
At this time, however, it is not known whether these RA
functions are applicable during foetal lung development.
On the other hand, clinical trials showed that vitamin A
supplementation given largely to infants <1 kg resulted in a
decrease in death and ⁄or BPD without increasing mortality
or neurodevelopment impairment at 18 to 22 months (Am-
balavanan et al. 2005). Thus, interventions with vitamin A
to treat infants with RDS and prevent its complications are
promising, but further research must be conducted (Carlo
et al. 2004). In order to contribute to a better knowledge
of vitamin A effects and its influence in the lung maturation
process we investigated if the antenatal administration of
vitamin A could alter the lung and plasma concentrations
of VEGF in foetuses and neonates.
Materials and methods
Animals
Mice, Mus musculus, strain ICR (CD-1; Harlan, Spain)
were housed at 22 C, fed ad libitum, and exposed to day–
night cycles alternatively every 12 h throughout the study
period. Mating was performed according to a polygamist
regimen (Broustail 1967). Timed-pregnant mice (visualiza-
tion of vaginal plug at day 0) were obtained on days 15–18.
Pregnant mice received a single subcutaneous injection of
vitamin A (150 ll, 45,000 IU of retinyl palmitate; G. Streuli
& Co., Uznach, Switzerland) on gestational day 12. At the
same gestational day, pregnant mice of control groups
received an equivalent volume of diluent alone (saturated
median chain triglyceraldehydes, Dub MCT 55 ⁄45 EP ex
Dubois, Georges Walther AG, Switzerland). Pregnant mice
and pups delivered naturally at term gestation were anaes-
thetized in the same manner. For anaesthesia induction, each
animal was placed alone in an induction chamber with gas
input and exhaust output lines. Anaesthesia was induced
with 5% isoflurane (Isoflo, Esteve Farma Lda., Carnaxide,
Portugal) in 100% oxygen with a delivery rate of 5 l ⁄min
until loss of righting reflex. The mothers were sacrificed by
neck dislocation and the foetuses were delivered by hysterec-
tomy. Pups were sacrificed by cutting large thoracic vessels.
The day of birth was designated day 0. Foetuses and neo-
nates were randomized to study groups (treated vs. control)
similar in number at each time point. All procedures and
protocols were approved by the Animal Care and Use Com-
mittee of the ‘Direc¸a˜o Geral de Veterina´ria, Portugal’.
Sample collection
Blood was collected from foetuses and neonates by cutting
large vessels in the thorax with a hand-modified 20G needle
(Sterican 100, B. Braun, Germany) applied to a 1 ml ⁄100 IU
syringe (Ominifix 100 solo, B. Braun, Germany) (Pinto et al.
2007, personal communication). The needle and syringe
were previously passed through a solution of ethylenedi-
aminetetraacetic acid tripotassium salt dihydrate (Sigma,
Steinheim, Germany) in NaCl 0.9% (B. Braun, Germany) at
25 mg ⁄ml. Whole blood was centrifuged at 2500 g for
2 min (Minispin, Eppendorf, Hamburg, Germany). Plasma
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was collected and stored at )80 C for further analysis.
Lungs were collected, frozen and stored at )80 C or pro-
cessed for paraffin embedding.
ELISA for VEGF
Frozen lungs were placed in 5 ml ice-cold phosphate-
buffered saline (PBS) and homogenized using a Potter-
Elvjhem homogenizer. The homogenates were centrifuged at
5000 g for 5 min at +4 C (Sigma 3K30, Steinheim, Ger-
many) and the supernatant was used to assay VEGF concen-
tration in lungs. ELISAs were performed with a commercial
VEGF ELISA kit (R&D Systems, Minneapolis, MN, USA)
according to the manufactures’ instructions. Briefly, stan-
dards and samples were incubated in duplicate wells of a
microplate coated with anti-VEGF polyclonal antibody.
Unbound substances were washed from the plate, and horse-
radish peroxidase-linked anti-VEGF polyclonal antibody was
added. After incubation and further washing, H2O2 and
tetramethylbenzidine were added. The reaction was stopped
with HCl, and optical densities were read at 450 nm (cor-
rection wavelength at 540 nm) on a multiskan plate reader
(Labsystems Multiskan MCC ⁄340; Vantaa, Finland).
Vascular endothelial growth factor concentration was calcu-
lated by comparison with a standard curve generated using
a four-parameter logistic curve-fit and on-board software.
Vascular endothelial growth factor concentrations were nor-
malized to total protein concentrations determined by the bi-
cinchoninic acid method. Each sample value is the result of
three lungs, and 36 lungs (18 treated vs. 18 controls) were
used at each time point. To assay the VEGF concentrations
in plasma the same procedure was applied, but the samples
were diluted (50 ll sample + 200 ll of calibrator diluent),
and 16 individual values (8 treated vs. 8 controls) were
obtained at each time point.
VEGF Immunostaining
Paraffin-embedded lung tissue sections (3 lm) were deparaff-
inized with xylene, and rehydrated through an ethanol–
water series. Antigen retrieval was performed by micro-
waving sections in Tris–HCl (10 mM Tris–HCl, pH 10.0).
Endogenous peroxidases activity was quenched using a 3%
solution of hydrogen peroxide. Sections were blocked with
‘Large volume ultra V block’ (Labvision Corporation,
Fremont, CA, USA). The slides were then incubated with
primary antibody (rabbit polyclonal anti-VEGF Ab-1,
5 lg ⁄ml, Labvision-Neomarkers, Fremont, CA, USA) over-
night at +4 C. Tissue sections were incubated with ‘Biotiny-
lated goat anti-polyvalent secondary antibody’, washed, and
incubated with ‘Large volume streptavidin peroxidase
reagent’. After being rinsed, the sections were incubated
with diaminobenzidine (Novocastra, UK) and counterstained
with haematoxylin. A negative control, using non-immune
goat serum instead of the primary antibody was used.
Lungs were viewed under a Nikon FX Photomicroscope
(Nikon, Japan) with a 40 · lens for immunohistochemical
scoring. The degree of positive staining was evaluated by
semi-quantitative scoring on a scale of 0 (negative cases) to
3 for intensity (I) and distribution (D) adapted from Ozer
et al. (2000). Tissues with I · D £ 3 were considered
weakly positive, and those with I · D > 3 were designated
strongly positive.
Statistical analysis
Data are expressed as mean ± SD. Statistical analysis was
performed using spss 13.0 (Chicago, IL, USA). After check-
ing both assumptions of normality and homogeneity of vari-
ances the one-way anova was used to analyse the different
groups. Immunohistochemical scores were assessed by the v2
test. Statistical significance was set at P < 0.05.
Results
Quantitative observations
VEGF pulmonary levels. The ELISA values obtained for
VEGF in the lungs of control and vitamin A treated foetuses
and neonates are displayed in Figure 1. At gestational day
15, VEGF levels in the lung homogenates from control
foetuses are higher (76.5 ± 15.1 ng VEGF ⁄mg total lung
protein; P = 0.004) than the ones observed in vitamin
A treated foetuses (48.05 ± 10.55 ng ⁄mg). From this day
onwards, VEGF levels in the lungs from vitamin A treated
foetuses increase gradually and reach a maximum of
192.7 ± 42.8 ng ⁄mg at the 18th gestational day. On the
opposite, VEGF levels in the lungs from control foetuses
suffer a nearly three-fold decrease (26.8 ± 5.4 ng ⁄mg) at the
16th gestational day. A statistically significant difference
(P < 0.0001) between control and treated foetuses is
observed at this day. Pulmonary VEGF levels increase to
70.2 ± 10.2 ng ⁄mg in control foetuses of 17 gestational
days, but decrease again to 48.4 ± 11.3 ng ⁄mg by the 18th
gestational day. A statistically significant difference
(P < 0.0001) between control and treated foetuses is also
observed at the 18th gestational day. However, at the day of
birth, VEGF pulmonary levels in control and vitamin A
treated neonates are similar (213.8 ± 37.8 for control and
188.7 ± 48.3 for treated). It is important to point out that
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pulmonary VEGF levels in vitamin A treated foetuses at the
18th gestational day are similar to those observed at the day
of birth, a tendency that is not observed in control subjects
(Table 1, Figure 1).
VEGF plasma levels. The results of VEGF quantification in
plasma are presented in Figure 2. Vascular endothelial
growth factor plasma levels in control foetuses and neonates
show a gradual and sustained increase throughout develop-
ment, ranging from 13.7 ± 3.2 pg ⁄ml at the 15th gestational
day to 52.6 ± 14.9 ng ⁄ml at the day of birth. A significant
increase takes place between the 15th and the 16th gesta-
tional days, in which VEGF plasma levels nearly triple
(Figure 2). At the 15th gestational day, VEGF plasma levels
in treated foetuses (28.1 ± 7.5 pg ⁄ml) more than double the
values observed in control foetuses, reaching a statistically
significant difference (P < 0.0001). A similar difference at
gestational day 16 is also observed (Table 2, Figure 2). A
prominent decrease in VEGF plasma levels from treated foe-
tuses occurs at the 17th gestational day. From this gesta-
tional day and until the day of birth, VEGF levels in treated
foetuses increase gradually, despite being inferior to the ones
observed in control (Table 2, Figure 2). The difference
between control and treated groups is statistically significant
(P < 0.05) at the 18th gestational day, the day before birth.
Qualitative and semi-quantitative observations
Immunostaining for VEGF protein revealed that in the foetal
and neonate lung VEGF is observed both in epithelial and
mesenchymal cells. Lungs from control foetuses with 15
gestational days display a strong immunoexpression for
VEGF regarding both intensity and distribution patterns
(Table 1, P < 0.05 vs. treated foetuses). Positive cells include
columnar and cuboidal cells in the tubular epithelium and
the surrounding mesenchymal cells (Figure 3a). At the same
age, VEGF immunoexpression in the lungs of treated foetus-
es is weak, but it is more pronounced in the mesenchyme
and in the areas where the interlobar septa will develop
(Figure 3b). At the late canalicular stage (16 gestational
days) VEGF pulmonary immunoexpression is weak in con-
trol subjects, but lungs from treated foetuses display a strong
immunoexpression for VEGF, in particular regarding the dis-
tribution pattern (Table 1, P < 0.05 vs. control foetuses).
Immunoexpression in the vascular endothelium was also






None Weak Moderate Strong None Weak Moderate Strong
15 0 0 2 2 0 4* 0 0
16 1 3 0 0 0 0 3* 1*
17 1 2 1 0 0 2 2 0
18 0 0 4 0 0 0 4 0
0 0 0 2 2 0 0 4 0
*P < 0.05 (vs. control).
Day of birth.
Figure 1 Vascular endothelial growth factor (VEGF) pulmonary
levels during foetal development expressed in ng of VEGF ⁄mg
of protein (mean ± SD). Sustained increase of VEGF in the lungs
from vitamin A treated foetuses. In the last gestational day,
VEGF levels are already similar to the ones observed in the
neonate lung. On the opposite, control foetuses display reduced
VEGF levels during the perinatal period. **P = 0.04 (vs.
control); *P < 0.0001 (vs. control).
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observed. At the 17th gestational day, both control and trea-
ted groups exhibit strong pulmonary VEFG immuno-
expression (Figure 3c,d), however, the distribution of VEGF
positive cells throughout lung parenchyma is not homoge-
neous. The central areas have fewer VEGF expressing cells
when compared with the peripheral lung areas, a finding
specially pronounced in the control group (Figure 3d). In the
lungs of treated foetuses at the late saccular period (18 ges-
tational days) VEGF immunoexpression intensity in the sac-
cular parenchyma reaches a peak (Figure 3f), but again the
distribution pattern is not homogeneous, and there are areas
where the expression is scarce or even absent (Figure 3e,f).
At this day, VEGF immunoexpression intensity is high in the
muscle cells of the vascular walls, but it is weak or even
absent in the cuboidal epithelium of the distal airways, both
in control and treated foetuses. At the day of birth, VEGF
pulmonary immunoexpression is very similar to that
observed on the last prenatal day, but there is a trend
towards a higher intensity in control animals, and a more
homogeneous distribution pattern in treated ones. At this
day, VEGF immunoexpression is observed in the epithelial
and endothelial cells of lung parenchyma (Figure 3g,h), as
well as in muscle cells of the walls of vascular and large
airways.
Figure 2 Vascular endothelial growth factor (VEGF) plasma
levels during foetal development expressed in pg of VEGF ⁄ml
(mean ± SD). Gradual increase of VEGF plasma levels through-
out development in control subjects. A prominent increase at
the 15th gestational day is observed, both in control and in
vitamin A treated foetuses. In the last gestational day, VEGF
plasma levels are higher in control foetuses, reaching a signifi-
cant statistical difference. At the day of birth, however, control
and treated animals display similar VEGF plasma levels.





Figure 3 Immunohistochemistry for vascular endothelial
growth factor (VEGF) in the lungs of control (a, c, e, g) and
vitamin A treated (b, d, f, h) foetuses and neonates. Higher
intensity and distribution of VEGF immunoexpression patterns
in control foetuses at the 15th gestational (a, b). Strong VEGF
immunoexpression, both for control and for treated foetuses at
the 17th gestational day (c, d). The central area depicted in (c)
displays fewer immunoexpressing cells. Higher immunoexpres-
sion in treated foetuses at the 18th gestational day (f). The
intensity and distribution expression patterns are different in
contiguous areas of the saccular parenchyma. Similar immu-
noexpression for VEGF in control and treated neonates (g, h).
Notice the weak or absent immunoexpression in the
cuboidal epithelium of the distal airways. Original
magnification ·400 (a, b and e, f). Original magnification ·200
(c, d and g, h).
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Discussion
Lung-branching morphogenesis and epithelial development
have been the subject of intense investigation over the past
50 years (Warburton et al. 2000; Cardoso 2001; Demayo
et al. 2002). Emerging data indicate that the formation of
pulmonary vascular units directs epithelial morphogenesis
but the precise signalling pathways involved in this process
are still to be determined (Warburton et al. 2000; Demayo
et al. 2002; Cardoso & Lu 2006). A biologically active
derivative of vitamin A, RA, plays an important role in both
the biochemical (surfactant) and structural maturation
(alveolarization) of the developing lung (Torday & Rehan
2004). A large number of physiological effects of VEGF per-
tain particularly to the lung, which is one of the organs with
the highest expression of VEGF in animal systems (Voelkel
et al. 2006).
This study was conducted to investigate if the antenatal
administration of vitamin A, in the period where its terato-
genic effects are no longer present, could alter VEGF expres-
sion in lungs and plasma from foetuses and neonates.
Our results show that vitamin A modulates VEGF expres-
sion in plasma and lungs of foetuses and neonates. Vitamin
A treated foetuses present higher VEGF pulmonary levels at
all but the 15th gestational day. A particularly critical and
delicate period, the antenatal day (18th gestational day),
presents the most striking difference in VEGF pulmonary
concentrations between control and treated foetuses. In fact,
VEGF pulmonary levels in treated foetuses are nearly four
times higher than the levels observed in control subjects. In
control foetuses, there is a peak in pulmonary VEGF con-
centrations at gestational day 17. This finding differs from
the reports made by Ng et al. (2001) and Chang et al.
(2004) who suggest that there is an increase in VEGF
expression throughout lung development, peaking at the
16th gestational day. This discrepancy may be explained by
the fact that the commercial ELISA kit used in our study
quantifies 120 and 164 mouse VEGF protein isoforms, leav-
ing out the VEGF188 isoform, and that we have quantified
proteins and not VEGF mRNAs isoforms, as in the previous
studies.
The precise regulation of VEGF pulmonary levels is of
critical importance since lung VEGF overexpression causes
lung dysmorphogenesis (Akeson et al. 2003). Decrease in
lung VEGF as a consequence of VEGF neutralization or gene
deletion results in poor septal formation and an emphysema-
tous pattern (Gerber et al. 1997). Disruption of the VEGF ⁄ -
VEGF receptor signalling not only reduces pulmonary
arterial density, but also leads to impaired alveolarization,
emphysema and pulmonary hypertension (Jakkula et al.
2000; Kasahara et al. 2000; Lassus et al. 2001). Further-
more, exogenous RA increases alveolar septal formation in
adult tight skin mice, a genetic model associated with a
failure in alveolar septation resulting in emphysema
(Massaro & Massaro 2000).
In our study, the morphologic observations revealed that
the lungs of treated animals did not display any abnormal
features. Previous studies made by our group (data not pub-
lished) have already indicated that the elastic fibres of the
lung’s interstitial compartment significantly increased in foe-
tuses and neonate mice from vitamin A treated mothers,
which is in accordance with the recent studies published by
Pierce et al. (2007).
The results of our study suggest that the beneficial effects
of vitamin A administration seem to work in a synergetic
manner with the modulating action of VEGF in lung tissue.
This is not surprising taking into account that RA indirectly
regulates visceral endoderm survival and production of solu-
ble signals, including VEGF (Bohnsack et al. 2004). More-
over, the presence of all-trans RA in rat lung cultured
endothelial cells increases their nitric oxide production,
which is one of the mediators of the VEGF effects (Uruno
et al. 2005). Additionally, it was also shown recently that
all-trans RA induces VEGF secretion in umbilical vein endo-
thelial cells culture (Saito et al. 2007).
Recent studies also demonstrate that RA attenuates the
mild hyperoxic lung injury of newborn mice, with effects on
VEGF mRNA expression (Zimova´ et al. 2007). Vascular
endothelial growth factor acts as a morphogen, inducing a
significant increase in both epithelial- and endothelial-
branching morphogenesis (Del Moral et al. 2006), and
accelerating lung growth in rat foetal lung explants (Shinkai
et al. 2006).
Our immunohistochemical results, regarding the intensity
scores from our study, are in accordance with the results
from the studies made by Zhao et al. (2005). However, there
is a slight discrepancy regarding the type of cells displaying
VEGF expression that may be explained by the different
techniques used. In the study by Zhao et al. (2005) it is men-
tioned that at the 18.5th gestational day VEGF expression is
restricted to a subpopulation of cells that line the saccular
walls, and there is no mention of VEGF expression by the
muscle cells of the vascular walls, as seen in our study. Even
so, they mention that they cannot rule out the expression by
other cells. The other cells would include endothelial cells, as
we already observed at the 16th gestational day, despite the
close proximity of epithelial and endothelial cells. Immuno-
staining of the vascular endothelium in the lung of foetuses
and preterm infants was also observed by Lassus et al.
(2001). It is interesting to notice that in term infants this was
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not apparent, and that VEGF increased rapidly in the tra-
cheal aspirates from preterm infants during the first days of
life (Lassus et al. 1999). Due to these findings the authors
suggested that VEGF may be indicative of pulmonary matu-
rity. Our observations revealed VEGF immunostaining of the
vascular endothelium also in term mice (day 0 of life), which
can be a normal feature of the mice lung.
To the best of our knowledge, this is the first report that
presents results on plasma VEGF levels in foetuses and neo-
nates. Vascular endothelial growth factor plasma levels were
previously determined by Lassus et al. (1999) in infants with
clinically diagnosed RDS. These authors demonstrated that
they remained constant during the first postnatal week. Our
results show that VEGF plasma levels suffer variations dur-
ing foetal development, and are modified by the maternal
administration of vitamin A. It is interesting to notice that
during our study, the days were significantly statistical dif-
ferences were observed regarding both VEGF plasma and
pulmonary levels, where precisely the same (15, 16 and 18
gestational days). Regarding this particular aspect, it is inter-
esting to consider the hypothesis raised by Kaner and Crys-
tal (2001), that high levels of VEGF protein on the
respiratory epithelial surface may function as a physiological
reservoir. If this is correct, we could then assume that the
variations of plasma VEGF levels during foetal development
would reflect VEGF variations in the developing lung, the
physiological reservoir. The same authors suggested that in
healthy humans VEGF protein levels in alveoli are 500 times
higher than in plasma. In the present study we cannot
directly compare VEGF plasma levels with the ones obtained
in the lung homogenates, since these last were normalized to
total protein concentrations. Nevertheless, there is a ten-
dency for the plasma and pulmonary VEGF levels to change
inversely, which could point out to the role of reservoir dis-
played by the lung, but further studies need to be made to
confirm this.
Blood VEGF data is affected by several confounding cir-
cumstances, including circadian rhythm and hypoxia.
Hypoxia is one of the major regulators of VEGF production
(Papaioannou et al. 2006; Voelkel et al. 2006). However, Olt-
manns et al. (2006) found that in contrast with in vitro studies
(Ferrara et al. 1992; Shweiki et al. 1992; Namiki et al. 1995;
Fredriksson et al. 2000; Mick et al. 2002), hypoxia decreases
plasma concentrations in adult human healthy subjects.
Therefore, systemic VEGF concentration may be differently
regulated than the expression on a cellular basis. Whether this
is also true for foetal development, and if the physiologic ‘hyp-
oxic environment’ of the developing foetus decreases VEGF in
plasma is still to be addressed. Circadian rhythm can also
affect VEGF blood levels, but in order to avoid variations
related to this factor the sacrifice and sample collection were
consistently made at the same hour of the day.
Despite very recent studies having demonstrated that the
repression of VEGF expression by premature birth and
mechanical ventilation was not altered by vitamin A supple-
mentation (Pierce et al. 2007), we demonstrated that maternal
vitamin A administration influences foetal and neonate VEGF
pulmonary and plasma levels, and that VEGF ⁄RA is one of
the signalling pathways involved in this process. Furthermore,
our data support the hypothesis that the maternal antenatal
vitamin A administration can enhance foetal lung develop-
ment. We may therefore speculate that, despite the differences
between lung alveolar development in mice and humans, vita-
min A antenatal administration could be beneficial for the
human foetus. However, further studies and clinical trials
must be performed to address this question. Bearing in mind
this perspective, the present results could make an important
contribution towards future appropriately designed strategies
to prevent the risk of RDS and BPD in premature neonates.
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